Raptis, Catherine ECatherine ERaptisBerger, Christoph TChristoph TBergerCiurea, AdrianAdrianCiureaAndrey, Diego ODiego OAndreyPolysopoulos, ChristosChristosPolysopoulosLescuyer, PierrePierreLescuyerMaletic, TanjaTanjaMaleticRiek, MyriamMyriamRiekScherer, AlmutAlmutScherervon Loga, IsabellIsabellvon LogaSafford, JudithJudithSaffordLauper, KimKimLauperMöller, BurkhardBurkhardMöller0000-0001-8769-6167Vuilleumier, NicolasNicolasVuilleumierFinckh, AxelAxelFinckhRubbert-Roth, AndreaAndreaRubbert-Roth2024-10-112024-10-112022https://boris-portal.unibe.ch/handle/20.500.12422/88562Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support COVID-19 vaccination strategies. We aimed to conduct a long-term, model-based comparison of the humoral immunogenicity following BNT162b2 and mRNA-1273 vaccination in a cohort of IRD patients. Patients from the Swiss IRD cohort (SCQM), who assented to mRNA COVID-19 vaccination were recruited between 3/2021-9/2021. Blood samples at baseline, 4, 12, and 24 weeks post second vaccine dose were tested for anti-SARS-CoV-2 spike IgG (anti-S1). We examined differences in antibody levels depending on the vaccine and treatment at baseline while adjusting for age, disease, and past SARS-CoV-2 infection. 565 IRD patients provided eligible samples. Among monotherapies, rituximab, abatacept, JAKi, and TNFi had the highest odds of reduced anti-S1 responses compared to no medication. Patients on specific combination therapies showed significantly lower antibody responses than those on monotherapy. Irrespective of the disease, treatment, and past SARS-CoV-2 infection, the odds of higher antibody levels at 4, 12, and 24 weeks post second vaccine dose were, respectively, 3.4, 3.8, and 3.8 times higher with mRNA-1273 versus BNT162b2 (p < 0.0001). With every year of age, the odds ratio of higher peak humoral immunogenicity following mRNA-1273 versus BNT162b2 increased by 5% (p < 0.001), indicating a particular benefit for elderly patients. Our results suggest that in IRD patients, two-dose vaccination with mRNA-1273 versus BNT162b2 results in higher anti-S1 levels, even more so in elderly patients.enBNT162b2 SARS-CoV-2 anti-spike-IgG immunosuppression mRNA-1273 rheumatic disease vaccination waning immunity600 - Technology::610 - Medicine & healtharticle10.48350/1743753631179110.3389/fimmu.2022.1016927